{"id":"csf-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CSF-1 (macrophage colony-stimulating factor) binds to the CSF-1 receptor on hematopoietic progenitor cells, stimulating their proliferation and differentiation into macrophages and other myeloid lineage cells. This mechanism is intended to support immune cell recovery and function, particularly in contexts of immune suppression or deficiency.","oneSentence":"CSF-1 is a recombinant human colony-stimulating factor 1 that promotes the growth and differentiation of myeloid progenitor cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:04.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune reconstitution and myeloid cell recovery in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT04710576","phase":"PHASE2","title":"A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2021-03-04","conditions":"Chronic Graft-versus-host-disease","enrollment":241},{"nctId":"NCT05479045","phase":"PHASE2","title":"A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Georgetown University","startDate":"2026-09","conditions":"Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3","enrollment":24},{"nctId":"NCT04936529","phase":"PHASE2","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-02","conditions":"Neuroblastoma","enrollment":286},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT02774421","phase":"PHASE1","title":"Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2017-06-12","conditions":"Posterior Fossa Ependymoma (PFEPN)","enrollment":33},{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT05806814","phase":"PHASE1","title":"Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2023-11-12","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":13},{"nctId":"NCT04144023","phase":"PHASE1","title":"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-06-27","conditions":"Breast Ductal Carcinoma In Situ","enrollment":43},{"nctId":"NCT04238819","phase":"PHASE1, PHASE2","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-09","conditions":"Relapsed Solid Tumor, Refractory Solid Tumor","enrollment":47},{"nctId":"NCT03363373","phase":"PHASE2","title":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","status":"RECRUITING","sponsor":"Y-mAbs Therapeutics","startDate":"2018-04-03","conditions":"Neuroblastoma","enrollment":122},{"nctId":"NCT06431776","phase":"PHASE3","title":"Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).","status":"RECRUITING","sponsor":"Savara Inc.","startDate":"2025-10-22","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":5},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT00458536","phase":"PHASE1, PHASE2","title":"Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-10","conditions":"Renal Cancer","enrollment":38},{"nctId":"NCT05602142","phase":"PHASE1, PHASE2","title":"Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"ALS","enrollment":20},{"nctId":"NCT05489887","phase":"PHASE2","title":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2022-09-14","conditions":"Neuroblastoma","enrollment":93},{"nctId":"NCT07377435","phase":"PHASE1","title":"DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT07342322","phase":"PHASE2","title":"A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-02-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":25},{"nctId":"NCT07341360","phase":"EARLY_PHASE1","title":"Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-10-13","conditions":"Pseudomyxoma Peritonei","enrollment":10},{"nctId":"NCT05544968","phase":"PHASE1","title":"Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma","enrollment":42},{"nctId":"NCT07327411","phase":"PHASE2","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-27","conditions":"Advanced Refractory Solid Tumors","enrollment":40},{"nctId":"NCT06546098","phase":"","title":"Molgramostim Nebulizer Solution Expanded Access Program Protocol","status":"AVAILABLE","sponsor":"Savara Inc.","startDate":"","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":""},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT07305675","phase":"NA","title":"Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars.","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2025-01-01","conditions":"Acne Scars - Atrophic, Wound Healing","enrollment":30},{"nctId":"NCT04902703","phase":"PHASE2","title":"Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-01","conditions":"Alzheimer Disease","enrollment":42},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT03069469","phase":"PHASE1, PHASE2","title":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2017-02-16","conditions":"Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath","enrollment":120},{"nctId":"NCT07077616","phase":"EARLY_PHASE1","title":"Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2025-07-01","conditions":"Glioma","enrollment":29},{"nctId":"NCT05307835","phase":"PHASE1","title":"Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-12-02","conditions":"Resectable Esophageal Cancer","enrollment":27},{"nctId":"NCT06626516","phase":"PHASE1, PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":"Metastatic Uveal Melanoma","enrollment":109},{"nctId":"NCT02800954","phase":"NA","title":"Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2009-02-23","conditions":"Multiple Myeloma","enrollment":111},{"nctId":"NCT06608303","phase":"NA","title":"Macrophage Stimulating Factor in the Treatment of Diabetic Wounds","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2024-10-12","conditions":"Diabetic Wound","enrollment":40},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":26},{"nctId":"NCT04237623","phase":"PHASE2","title":"GM-CSF With Post-Transplant Cyclophosphamide","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2020-05-18","conditions":"Transplant-Related Hematologic Malignancy","enrollment":38},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT00669734","phase":"PHASE1","title":"Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":18},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT03033303","phase":"PHASE2","title":"A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-23","conditions":"Neuroblastoma","enrollment":59},{"nctId":"NCT02502786","phase":"PHASE2","title":"Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-07","conditions":"Recurrent Osteosarcoma","enrollment":46},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT03604692","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2018-11-01","conditions":"Chronic Graft-versus-host-disease","enrollment":41},{"nctId":"NCT02361528","phase":"PHASE3","title":"GM-CSF to Decrease ICU Acquired Infections","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-09-14","conditions":"Septic Shock, Severe Sepsis","enrollment":166},{"nctId":"NCT06799026","phase":"PHASE1","title":"A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"David Avigan","startDate":"2025-01-31","conditions":"Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":25},{"nctId":"NCT04544293","phase":"PHASE3","title":"Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Savara Inc.","startDate":"2021-05-19","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":164},{"nctId":"NCT05717140","phase":"PHASE1","title":"Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2025-10-28","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma","enrollment":""},{"nctId":"NCT04963413","phase":"PHASE1","title":"RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.","status":"TERMINATED","sponsor":"University of Florida","startDate":"2022-01-13","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT07090538","phase":"EARLY_PHASE1","title":"GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-08-01","conditions":"Neuroblastoma","enrollment":10},{"nctId":"NCT06651853","phase":"PHASE2","title":"Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-10-21","conditions":"Diffuse Large B-cell Lymphoma, Relapsed and Refractory","enrollment":22},{"nctId":"NCT07027748","phase":"PHASE1","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Steven DuBois, MD","startDate":"2025-06-27","conditions":"Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma","enrollment":18},{"nctId":"NCT03189706","phase":"EARLY_PHASE1","title":"Study of Chemoimmunotherapy for High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-06-12","conditions":"Neuroblastoma (NB)","enrollment":48},{"nctId":"NCT06013618","phase":"PHASE2","title":"Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2023-06-19","conditions":"Neuroblastoma","enrollment":120},{"nctId":"NCT05393895","phase":"PHASE3","title":"An Evaluation of the Safety of CSF-1 in Presbyopic Subjects","status":"COMPLETED","sponsor":"Orasis Pharmaceuticals Ltd.","startDate":"2022-04-22","conditions":"Presbyopia","enrollment":178},{"nctId":"NCT06989333","phase":"PHASE2","title":"Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","status":"NOT_YET_RECRUITING","sponsor":"Jiuwu Bai","startDate":"2025-07-01","conditions":"Pulmonary Alveolar Proteinosis","enrollment":10},{"nctId":"NCT00661622","phase":"PHASE2","title":"Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2004-10","conditions":"Uveal Melanoma, Liver Metastases","enrollment":53},{"nctId":"NCT04072042","phase":"PHASE2","title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-10-30","conditions":"Sarcoma","enrollment":30},{"nctId":"NCT04040231","phase":"PHASE1","title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-24","conditions":"Mesothelioma, Pleural Mesothelioma, Wilms Tumor","enrollment":10},{"nctId":"NCT03600350","phase":"PHASE2","title":"pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2018-09-10","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT06961409","phase":"","title":"Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions","status":"RECRUITING","sponsor":"Izmir Katip Celebi University","startDate":"2024-08-14","conditions":"Periodontal Diseases, Periodontitis, Gingivitis","enrollment":60},{"nctId":"NCT06216938","phase":"EARLY_PHASE1","title":"RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis","status":"RECRUITING","sponsor":"Yana Najjar","startDate":"2024-03-07","conditions":"Melanoma","enrollment":25},{"nctId":"NCT00436254","phase":"PHASE1","title":"Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2001-10","conditions":"HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor","enrollment":66},{"nctId":"NCT05482334","phase":"PHASE2","title":"Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2023-10-23","conditions":"Down Syndrome","enrollment":""},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT01903330","phase":"PHASE2","title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2014-03","conditions":"Glioblastoma, Gliosarcoma","enrollment":84},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04447469","phase":"PHASE2, PHASE3","title":"Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation","status":"COMPLETED","sponsor":"Kiniksa Pharmaceuticals International, plc","startDate":"2020-07-28","conditions":"COVID","enrollment":814},{"nctId":"NCT02465268","phase":"PHASE2","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-08-09","conditions":"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma","enrollment":175},{"nctId":"NCT04856176","phase":"PHASE2","title":"A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2022-01-03","conditions":"Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":5},{"nctId":"NCT03866525","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2019-04-02","conditions":"Solid Tumor, Gastrointestinal Cancer","enrollment":300},{"nctId":"NCT05266001","phase":"PHASE3","title":"GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2022-06-14","conditions":"Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome","enrollment":141},{"nctId":"NCT02275416","phase":"PHASE1, PHASE2","title":"Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2015-02-02","conditions":"Malignant Melanoma","enrollment":12},{"nctId":"NCT01789099","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2013-04-08","conditions":"Non-small Cell Lung Cancer","enrollment":18},{"nctId":"NCT01784913","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2013-04-15","conditions":"Prostate Cancer","enrollment":22},{"nctId":"NCT06722131","phase":"","title":"Biobank of Samples From Patients With Infectious Diseases","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-01","conditions":"Infectious Diseases","enrollment":1000},{"nctId":"NCT03304821","phase":"PHASE2","title":"Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2017-12-19","conditions":"Peripheral Artery Disease (PAD)","enrollment":176},{"nctId":"NCT01266083","phase":"PHASE2","title":"WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2011-01-14","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":22},{"nctId":"NCT03761914","phase":"PHASE1, PHASE2","title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2019-09-30","conditions":"Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer","enrollment":26},{"nctId":"NCT01265433","phase":"PHASE2","title":"Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2010-12-21","conditions":"Malignant Pleural Mesothelioma","enrollment":41},{"nctId":"NCT03686683","phase":"PHASE3","title":"Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2018-10-18","conditions":"Adenocarcinoma of the Prostate","enrollment":532},{"nctId":"NCT01346358","phase":"PHASE1","title":"A Study of IMC-CS4 in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-06-15","conditions":"Neoplasms","enrollment":52},{"nctId":"NCT01827137","phase":"PHASE1, PHASE2","title":"WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2013-04","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT06438614","phase":"PHASE2","title":"A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2020-08-20","conditions":"Refractory Neuroblastoma, Soft Tissue Cancer","enrollment":47},{"nctId":"NCT04013672","phase":"PHASE2","title":"Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence","status":"COMPLETED","sponsor":"David Peereboom","startDate":"2020-03-19","conditions":"Recurrent Glioblastoma","enrollment":41},{"nctId":"NCT03538314","phase":"PHASE1","title":"UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2018-07-09","conditions":"Malignant Melanoma","enrollment":30},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT00487305","phase":"PHASE1","title":"Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-06","conditions":"Follicular Lymphoma","enrollment":24},{"nctId":"NCT03455764","phase":"PHASE1, PHASE2","title":"MCS110 With BRAF/MEK Inhibition in Patients With Melanoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-09-10","conditions":"Melanoma","enrollment":6},{"nctId":"NCT04739618","phase":"PHASE2","title":"Metastatic Solid Cancer Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunSYS, LLC","startDate":"2021-03-04","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT00901511","phase":"PHASE2","title":"Inhaled GM-CSF Therapy of Autoimmune PAP","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2009-07","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":18},{"nctId":"NCT03502330","phase":"PHASE1","title":"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-06-09","conditions":"Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma","enrollment":42},{"nctId":"NCT03482752","phase":"PHASE3","title":"Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis","status":"TERMINATED","sponsor":"Savara Inc.","startDate":"2018-04-16","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":60},{"nctId":"NCT06472739","phase":"PHASE2","title":"The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-15","conditions":"GM-CSF","enrollment":138},{"nctId":"NCT00799110","phase":"PHASE2","title":"Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-08","conditions":"Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":23},{"nctId":"NCT04404361","phase":"PHASE2","title":"PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2020-05-22","conditions":"COVID19, COVID-19, COVID","enrollment":200},{"nctId":"NCT03238027","phase":"PHASE1","title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2017-09-01","conditions":"Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm","enrollment":45},{"nctId":"NCT04121208","phase":"PHASE1","title":"MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2021-04-07","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2620,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Qlosi","pilocarpine HCl 0.4%"],"phase":"phase_3","status":"active","brandName":"CSF-1","genericName":"CSF-1","companyName":"Orasis Pharmaceuticals Ltd.","companyId":"orasis-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSF-1 is a recombinant human colony-stimulating factor 1 that promotes the growth and differentiation of myeloid progenitor cells. Used for Immune reconstitution and myeloid cell recovery in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}